Biotech News
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026.
Related news
ANIPANI Pharmaceuticals2026-10-23 10:55 EST
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
ANIPANI Pharmaceuticals2025-11-07 11:50 EST
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
AMRXAmneal Pharmaceuticals2026-11-03 11:00 EST
Amneal Reports Third Quarter 2026 Financial Results
CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
AMRXAmneal Pharmaceuticals2026-07-30 10:00 EST
Amneal Reports Second Quarter 2026 Financial Results
CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
ALVOAlvotech2026-10-28 11:00 EST
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
ALVOAlvotech2026-08-19 20:30 EST
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
ANI Pharmaceuticals
Rare-Disease and Specialty Pharmaceuticals ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets. Its model combines branded specialty products with a portfolio of generic medicines. Cortrophin Gel Purified Cortrophin Gel is an adrenocorticotropic hormone...
Recent company news
ANIPANI Pharmaceuticals2026-11-05 11:51 EST
ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
ANIPANI Pharmaceuticals2026-11-05 11:50 EST
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
ANIPANI Pharmaceuticals2026-11-05 06:33 EST
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
ANIPANI Pharmaceuticals2026-11-03 11:55 EST
ANI Pharmaceuticals to Present at Upcoming November Investor Conferences
ANIPANI Pharmaceuticals2026-10-23 10:55 EST
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
Stock data
- Close
- 69.62 USD
- Market cap
- 1.7B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States